A world leading microbiome team on a mission
– Dr Sam Costello
Managing Director & Co-founder
Dr Sam Costello is a gastroenterologist and world leader in microbial therapeutic and faecal microbiota transplantation (FMT) trials.
Sam has published over 70 research papers with a focus on clinical trials of microbiome-based therapies.
Sam founded the South Australian FMT service in 2013 and co founded BiomeBank in 2018. He has also led the establishment of BiomeBank’s Biomictra program.
Read his research papers here.
Dr Rob Bryant is a consultant gastroenterologist and leading expert in clinical trials in inflammatory bowel disease.
Rob has published over 80 research papers with a clinical and research focus on microbiome-based and dietary therapies for inflammatory bowel disease. He is head of IBD service at The Queen Elizabeth Hospital and co-founded BiomeBank in 2018.
Read his research papers here.
Investment manager with over 30 years of experience. Held senior portfolio management and business leadership roles in Asia and Australia with Blackrock Asset Management, Ellerston Capital., Goldman Sachs JB Were, and Argo Investments.
He currently, holds several board positions including, Chair of Perks Private Wealth Investment Committee, and Non-Executive Director of Funds SA.
Founder, Director and manager of a number of successful medical devices and life sciences companies including director of Austofix, StratifEYE, Icsion.
He also serves as Trustee of a Charitable foundation.
CEO of the Hospital Research Foundation (THRF), Director of Prostate Cancer, and Director and Vice Chairman of the Fundraising Institute of Australia.
Paul also sits on the board of governors for THRF group.
The Management Team
Aurelie is a pharmacist and quality expert with more than a decade of experience developing and implementing quality systems at Novartis and other companies in France and Australia.
She established and built BiomeBank’s TGA approved Quality Management System for Biomictra.
Jarek Kopias is a CFO and Company Secretary with over 25 years’ experience in finance and governance roles. He has held executive positions at multiple companies managing their ASX IPO process and finance function. Currently Company Secretary of multiple ASX
She has led the submission and secured the world’s first regulatory approval of BiomeBank’s donor derived microbiome therapy.
Lisa is a microbiologist with a PhD and more than 10 years in industry and academia. Her academic research was in understanding complex microbial ecology.
Lisa established BiomeBank’s culturing workflow and leads the BB265 (defined therapy for ulcerative colitis) and scaffold projects. She contributes to the development of advanced microbiological techniques and methodology.
Garrett is a live biotherapeutic product expert with over 5 years industry specific experience leading live bacterial therapy process development and GMP manufacturing.
He relocated from the US to Australia to join BiomeBank.
Sarah is a PhD scientist with over 5 years experience designing and coordinating clinical trials in North America and Australia.
She has experience with FDA and TGA governed clinical trials and co-ordinating hospital sites on large multicentre studies.
Chelsea is an experienced process development scientist. She spent over 5 years at CSIRO prior to joining BiomeBank in 2019.
Chelsea established BiomeBank’s GMP manufacturing workflow and associated protocols.
Lori Wakelin is an administrator with more than 20 years experience in the FMCG industry including global companies Diageo and Red Bull prior to joining BiomeBank in 2020.